Differentiation Potential of Hypodifferentiated Subsets of Nephrogenic Rests and Its Relationship to Prognosis in Wilms Tumor

References

• Nakata K, Colombet M, Stiller CA, Pritchard‐Jones K, Steliarova‐Foucher E, IICC-3 Contributors. Incidence of childhood renal tumours: an international population‐based study. Int J Cancer. 2020;147(12):3313–27. doi:10.1002/ijc.33147.
   PubMed Web of Science ®Google Scholar
• Fernandez CV, Perlman EJ, Mullen EA, Chi Y-Y, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, et al. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor. Ann Surg. 2017;265(4):835–40. doi:10.1097/SLA.0000000000001716.
   PubMed Web of Science ®Google Scholar
• Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, Thomas PR, Kim T, Shochat S, Haase G, Ritchey M, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol. 1998;16(12):3744–51. doi:10.1200/JCO.1998.16.12.3744.
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K, Moroz V, Vujanić G, Powis M, Walker J, Messahel B, Hobson R, Levitt G, Kelsey A, Mitchell C, et al. Treatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol. 2012;23(9):2457–63. doi:10.1093/annonc/mds025.
   PubMed Web of Science ®Google Scholar
• Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, et al. Treatment of Anaplastic Histology Wilms’ Tumor: results From the Fifth National Wilms’ Tumor Study. J Clin Oncol. 2006;24(15):2352–8. doi:10.1200/JCO.2005.04.7852.
   PubMed Web of Science ®Google Scholar
• Hol JA, Lopez-Yurda MI, Van Tinteren H, Van Grotel M, Godzinski J, Vujanic G, Oldenburger F, De Camargo B, Ramírez-Villar GL, Bergeron C, et al. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001. PLoS One. 2019;14(8):e0221373. doi:10.1371/journal.pone.0221373.
   PubMed Web of Science ®Google Scholar
• Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen Q-R, et al. A Children’s Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor. Nat Genet. 2017;49(10):1487–94. doi:10.1038/ng.3940.
   PubMed Web of Science ®Google Scholar
• Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, et al. Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: a Report From the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312–21. doi:10.1200/JCO.2005.01.2799.
   PubMed Web of Science ®Google Scholar
• Gratias EJ, Dome JS, Jennings LJ, Chi Y-Y, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, et al. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: a Report From the Children’s Oncology Group. J Clin Oncol. 2016;34(26):3189–94. doi:10.1200/JCO.2015.66.1140.
   PubMed Web of Science ®Google Scholar
• Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, et al. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J Clin Oncol. 2016;34(26):3195–203. doi:10.1200/JCO.2015.66.0001.
   PubMed Web of Science ®Google Scholar
• Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, et al. TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia. PLoS One. 2014;9(10):e109924. doi:10.1371/journal.pone.0109924.
   PubMed Web of Science ®Google Scholar
• Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ, Ferdinand JR, Collord G, Botting RA, Popescu D-M, Loudon KW, et al. Single cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science. 2018;361(6402):594–9. doi:10.1126/science.aat1699.
   PubMed Web of Science ®Google Scholar
• Perlman EJ, Faria P, Soares A, Hoffer F, Sredni S, Ritchey M, Shamberger RC, Green D, Beckwith JB, National Wilms Tumor Study Group Hyperplastic perilobar nephroblastomatosis: long-term survival of 52 patients. Pediatr Blood Cancer. 2006;46(2):203–21. Feb doi:10.1002/pbc.20386.
   PubMed Web of Science ®Google Scholar
• Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4. doi:10.1038/nature09807.
   PubMed Web of Science ®Google Scholar
• Luecken MD, Theis FJ. Current best practices in single‐cell RNA‐seq analysis: a tutorial. Mol Syst Biol. 2019;15(6):e8746.
   PubMed Web of Science ®Google Scholar
• Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, Lennon NJ, Livak KJ, Mikkelsen TS, Rinn JL, et al. Pseudo-temporal ordering of individual cells reveals dynamics and regulators of cell fate decisions. Nat Biotechnol. 2014;32(4):381–6. doi:10.1038/nbt.2859.
   PubMed Web of Science ®Google Scholar
• Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, Zhang F, Mundlos S, Christiansen L, Steemers FJ, et al. The single cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566(7745):496–502. doi:10.1038/s41586-019-0969-x.
   PubMed Web of Science ®Google Scholar
• Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, Zhang Y, Zhao W, Zhou F, Li W, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12(1):2540. doi:10.1038/s41467-021-22801-0.
   PubMed Web of Science ®Google Scholar
• Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573–87.e29. doi:10.1016/j.cell.2021.04.048.
   PubMed Web of Science ®Google Scholar
• Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb)). 2021;2(3):100141. doi:10.1016/j.xinn.2021.100141.
   PubMedGoogle Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–3. doi:10.1093/bioinformatics/btq170.
   PubMed Web of Science ®Google Scholar
• Wang Z, Guo X, Gao L, Wang Y, Ma W, Xing B. Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients. Aging. 2020;12(18):18297–321. doi:10.18632/aging.103695.
   PubMedGoogle Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559. doi:10.1186/1471-2105-9-559.
   PubMed Web of Science ®Google Scholar
• Therneau TM. Until TL (original S > R port and R maintainer 2009), Atkinson Elizabeth, Crowson Cynthia, survival: survival Analysis. 2023. https://CRAN.R-project.org/package=survival
   Google Scholar
• Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: drawing Survival Curves using “ggplot2”. 2021. https://CRAN.R-project.org/package=survminer
   Google Scholar
• Journal of Open Source Software: visualizations with statistical details: the “ggstatsplot” approach [Internet]. 2023. doi:10.21105/joss.03167.
   Google Scholar
• Long J, Wang D, Wang A, Chen P, Lin Y, Bian J, Yang X, Zheng M, Zhang H, Zheng Y, et al. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Med. 2022;14(1):20. doi:10.1186/s13073-022-01024-y.
   PubMed Web of Science ®Google Scholar
• Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1–22. doi:10.18637/jss.v033.i01.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. doi:10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–97. doi:10.1002/sim.5958.
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, Panageas KS. How To Build and Interpret a Nomogram for Cancer Prognosis. J Clin Oncol. 2008;26(8):1364–70. doi:10.1200/JCO.2007.12.9791.
   PubMed Web of Science ®Google Scholar
• Jr FEH. rms: regression Modeling Strategies [Internet]. 2023. https://CRAN.R-project.org/package=rms
   Google Scholar
• Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, McGinn T, Guyatt G. Discrimination and Calibration of Clinical Prediction Models: users’ Guides to the Medical Literature. JAMA. 2017;318(14):1377–84. doi:10.1001/jama.2017.12126.
   PubMed Web of Science ®Google Scholar
• Longato E, Vettoretti M, Di Camillo B. A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models. J Biomed Inform. 2020;108:103496. doi:10.1016/j.jbi.2020.103496.
   PubMed Web of Science ®Google Scholar
• Kolde R. Pheatmap: pretty Heatmaps [Internet]. 2019. https://CRAN.R-project.org/package=pheatmap
   Google Scholar
• Sinha D, Kumar A, Kumar H, Bandyopadhyay S, Sengupta D. dropClust: efficient clustering of ultra-large scRNA-seq data. Nucleic Acids Res. 2018;46(6):e36–e36. doi:10.1093/nar/gky007.
   PubMed Web of Science ®Google Scholar
• Hennigar RA, O'Shea PA, Grattan-Smith JD. Clinicopathologic features of nephrogenic rests and nephroblastomatosis. Adv Anat Pathol. 2001;8(5):276–89. doi:10.1097/00125480-200109000-00005.
   PubMed Web of Science ®Google Scholar
• Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining Childhood and Adolescent Cancer Mortality. Cancer. 2014;120(16):2497–506. doi:10.1002/cncr.28748.
   PubMed Web of Science ®Google Scholar
• Vujanić GM, Apps JR, Moroz V, Ceroni F, Williams RD, Sebire NJ. Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: the UK SIOP Wilms Tumor 2001 Trial experience. Pediatr Blood Cancer. 2017;64(11):e26547.
   Web of Science ®Google Scholar
• Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240–51. doi:10.1038/s41581-019-0112-0.
   PubMed Web of Science ®Google Scholar
• Coppes MJ, Arnold M, Beckwith JB, Ritchey ML, D'Angio GJ, Green DM, Breslow NE. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer. 1999;85(7):1616–25. doi:10.1002/(SICI)1097-0142(19990401)85:7<1616::AID-CNCR26>3.0.CO;2-4.
   PubMed Web of Science ®Google Scholar
• Ehrlich PF, Tornwall B, Chintagumpala MM, Chi Y-Y, Hoffer FA, Perlman EJ, Kalapurakal JA, Warwick A, Shamberger RC, Khanna G, et al. Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children’s Oncology Group Study AREN0534. Ann Surg Oncol. 2022;29(5):3252–61. doi:10.1245/s10434-021-11266-6.
   PubMed Web of Science ®Google Scholar
• Koppenhafer SL, Goss KL, Voigt E, Croushore E, Terry WW, Ostergaard J, Gordon PM, Gordon DJ. Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma. Oncogene. 2022;41(20):2873–84. doi:10.1038/s41388-022-02310-0.
   PubMed Web of Science ®Google Scholar
• Kim HR, Moon JH, Lee JH, Lim YC. Inhibitor of DNA Binding 2 (ID2): A Novel Marker for Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. Ann Surg Oncol. 2021;28(11):6479–88. doi:10.1245/s10434-021-09832-z.
   PubMed Web of Science ®Google Scholar
• Li Z, Xie J, Fei Y, Gao P, Xie Q, Gao W, Xu Z. GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN. Biochem Biophys Res Commun. 2019;510(3):339–44. doi:10.1016/j.bbrc.2018.12.169.
   PubMed Web of Science ®Google Scholar